Name: 글로벌 시장 동향
SKU: PH7247
Availability: InStock

보고서 요약(국문)

개요
전 세계 원발성 담즙성 담관염 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
원발성 담즙성 담관염(PBC), 이전에는 원발성 담즙성 간경변증으로 불렸던 이 질환은 간내 담관이 점진적으로 파괴되어 문맥 주변 염증과 담즙 정체를 유발하는 자가면역 질환입니다. 장기간의 간 담즙 정체는 결국 간경변증과 문맥 고혈압을 초래합니다. 본 연구에서는 원발성 담즙성 담관염의 진단 및 치료, 그리고 이 질환을 가진 환자를 진단하고 관리하는 데 있어 다학제적 의료팀의 중요성을 검토합니다.
원발성 담즙성 담관염의 병태생리는 유전적 소인과 환경적 요인의 상호작용과 관련이 있는 것으로 여겨집니다. 직계 가족에서 질병 유병률이 11배로 높게 나타나는 것은 유전적 소인을 시사합니다. 일란성 쌍둥이에서도 높은 일치율을 보입니다. 원발성 담즙성 간경변증 환자의 딸은 이 질환 발병 위험이 가장 높습니다.
DRB1, DR3, DPB1, DQA1, DQB1을 포함한 여러 인간 백혈구 항원(HLA) 대립유전자가 원발성 담즙성 간경변증과 연관되어 있는 것으로 보고되었습니다. HLA-DRB1*08은 유럽 및 아시아계에서 흔하며, HLA-DRB1*11은 보호 효과가 있는 것으로 알려져 있습니다.
시장 동향: 성장 요인 및 제약 요인
원발성 담즙성 간경변증 치료를 위한 신약 개발 연구 개발 증가
현재 원발성 담즙성 간경변증을 완치할 수 있는 치료법은 없지만, 다양한 치료를 통해 질병의 진행을 늦출 수 있습니다. 제약 회사들은 원발성 담즙성 담관염에 대한 보다 효과적인 치료법을 개발하기 위해 연구 개발에 막대한 투자를 하고 있습니다. 따라서 개발 중인 새로운 약물들을 비롯한 많은 새로운 것들이 있습니다. 셀라델파는 3상 임상시험이 진행 중이며, 환자 모집이 임박했습니다. 엘라피브라노르 또한 3상 임상시험이 진행 중이며, 환자 모집이 임박했습니다. 이들은 PPAR 및 PPAR-α 이중 작용제입니다. PPAR-α-γ 이중 작용제인 사로글리타자르도 임상시험 중입니다. 오베티콜산과 베자피브레이트의 고정 용량 병용 요법에 대한 연구도 진행 중입니다.
예를 들어, 2023년 9월 사이마베이 테라퓨틱스(CBAY)는 원발성 담즙성 담관염 환자를 대상으로 한 셀라델파의 3상 핵심 연구인 RESPONSE 연구에서 긍정적인 결과를 발표했습니다. 본 연구는 원발성 담즙성 담관염 성인 환자 치료를 위해 개발 중인 강력하고 선택적인 경구 투여용 델파르 또는 PPARγ 작용제인 셀라델파르의 안전성과 효능을 평가했습니다.
또한, 원발성 담즙성 담관염은 장기적인 관리가 필요한 만성 질환이므로, 이 시장은 원발성 담즙성 담관염 유병률 증가, 치료법 발전, 질병에 대한 인식 제고 등 여러 요인에 의해 성장하고 있습니다.
시장 동향: 제약 요인
원발성 담즙성 담관염은 합병증을 동반하며, 이는 다른 제약 요인들과 함께 시장 성장을 저해하는 요인입니다. 원발성 담즙성 담관염을 치료하지 않거나 진행시키면 골다공증, 문맥고혈압, 복수, 비타민 결핍, 그리고 간암 위험 증가로 이어질 수 있습니다. 골다공증은 뼈가 약해지는 질환이고, 문맥고혈압은 복부 혈관의 혈압을 상승시키며, 복수는 체액 축적을 유발하고, 비타민 결핍은 간암 위험을 증가시킵니다. 또한, 원발성 담즙성 담관염에 대한 인식 부족, 조기 진단의 어려움, 그리고 제한적인 치료 옵션은 원발성 담즙성 담관염 치료제 시장의 성장을 저해할 것으로 예상됩니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 원발성 담즙성 담관염 시장은 병기, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 유형 부문에서 우르소데옥시콜산(UDCA)은 시장 점유율의 약 41.2%를 차지했습니다.
우르소데옥시콜산(UDCA)은 약물 유형 부문에서 41.2%를 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 우르소데옥시콜산(UDCA)은 이차 담즙산으로, 간에서 생성되는 일차 담즙산의 세균 대사산물입니다. 이는 두 가지 주요 인체 담즙산 중 하나인 케노데옥시콜산의 C7 에피머입니다. 우르소데옥시콜산(UCDA)은 원발성 담즙성 간염에 대해 승인된 유일한 1차 치료제로, 질병 진행을 늦추고 간 이식 필요성을 줄여줍니다. 그러나 임상 진행이 느리기 때문에 장기적인 치료 결과 평가는 어렵습니다.
예를 들어, 2023년 6월 입센과 젠핏은 핵심 3상 임상시험인 엘라티브(ELATIVE)에서 긍정적인 주요 결과를 발표했습니다. 이 임상시험에서는 희귀 담즙성 간 질환인 원발성 담즙성 간염 환자 중 현재 표준 치료제인 우르소데옥시콜산에 대한 반응이 불충분하거나 내약성이 없는 환자를 대상으로, 연구 단계의 이중 α,δ PPAR 작용제인 엘라피브라노르의 효능과 안전성을 평가했습니다.

지리적 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 잘 구축된 의료 인프라, 주요 시장 참여 기업의 존재, 그리고 최근 신제품 출시로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다. 또한, 원발성 담즙성 간경변증 환자 수의 증가와 치료제 수요 증가가 예측 기간 동안 시장 성장을 촉진할 것으로 전망됩니다.
예를 들어, 2023년 7월, 아스클레티스 파마(Ascletis Pharma Inc.)의 자회사인 가넥스 파마(Gannex Pharma Co., Ltd.)는 새로운 파네소이드 X 수용체(FXR) 작용제인 ASC42의 2상 임상 시험에 원발성 담즙성 간경변증 환자 98명의 등록을 완료했다고 발표했습니다.

또한, 2023년 6월 인터셉트 파마슈티컬스(Intercept Pharmaceuticals, Inc.)는 희귀 및 중증 간 질환에 대한 집중도를 높이고 운영 비용을 대폭 절감하기 위한 구조조정을 발표했는데, 여기에는 비알코올성 지방간염(NASH) 관련 투자를 전면 중단하는 것도 포함되었습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 응급 상황이 아닌 의료 서비스 연기 등으로 여러 의료 산업에 영향을 미치면서 원발성 담즙성 담관염 치료제 산업에도 부정적인 영향을 미쳤습니다. 팬데믹으로 인해 임상 시험을 포함한 연구 활동이 중단되고, 환자 모집 및 신제품 개발에 제약이 생겼습니다.

그러나 봉쇄 조치가 완화되고 COVID-19 확진자 수가 감소함에 따라 기업들은 원발성 담즙성 담관염 치료제에 대한 수요를 충족하기 위해 생산 활동을 재개했습니다. 또한, 제품 승인 증가와 원발성 담즙성 담관염 치료제 연구 개발 증가는 원발성 담즙성 담관염 치료제 시장의 성장을 견인하고 있습니다.

경쟁 환경
원발성 담즙성 담관염 시장의 주요 글로벌 업체로는 Intercept Pharmaceuticals, Inc., Ice Pharma, Sun Pharma, Wellona Pharma, Zoic Life Sciences, Steris Healthcare, Cadila Pharma, Cipla, Brunet, AstraEureka Pharmaceuticals 등이 있습니다.
주요 개발 사항
 2022년 6월, Intercept Pharmaceuticals Inc.는 원발성 담즙성 담관염 환자를 대상으로 한 두 가지 임상 연구, 즉 3b/4상 확증 임상 결과 연구인 Ocaliva COBALT와 HEROES 실증 연구 중 하나인 HEROES-US의 결과를 발표했습니다.  2022년 5월, 인터셉트 파마슈티컬스(Intercept Pharmaceuticals, Inc.)는 우르소데옥시콜산에 충분한 생화학적 반응을 보이지 않는 원발성 담즙성 담관염 환자 치료를 위해 오베티콜산(OCA)과 베자피브레이트(BZF)의 고정 용량 복합제를 평가하는 2상 임상시험에서 최초 환자에게 투약을 시작했다고 발표했습니다.
 2022년 5월, 인터셉트 파마슈티컬스는 유럽에서 특수 의약품 및 병원 의약품에 전략적으로 집중하는 제약 회사인 어드밴즈 파마(Advanz Pharma)와 인터셉트의 해외 사업 관련 일부 해외 자회사 및 권리를 매각하는 계약을 체결했다고 발표했습니다. 이 계약에는 미국 이외 지역에서 오칼리바(오베티콜산)를 상업화할 수 있는 라이선스가 포함됩니다.
보고서 구매 이유:

• 전 세계 원발성 담즙성 담관염 치료 시장을 단계별, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화하고 주요 상업 자산과 주요 업체를 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 원발성 담즙성 담관염 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 원발성 담즙성 담관염 치료 시장 보고서는 약 69개의 표, 70개의 그림, 185페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Primary Biliary Cholangitis Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Primary Biliary Cholangitis (PBC), formerly termed primary biliary cirrhosis, is an autoimmune disorder that leads to the gradual destruction of intrahepatic bile ducts, resulting in periportal inflammation and cholestasis. Prolonged hepatic cholestasis subsequently causes cirrhosis and portal hypertension. This activity reviews the evaluation and treatment of primary biliary cholangitis and the importance of the interprofessional team in recognizing and managing patients with this condition.
The pathogenesis of primary biliary cholangitis is thought to be related to the interaction between genetic predisposition and environmental triggers. The genetic predisposition is suggested by a strong prevalence of the disease in first-degree relatives, with an odds ratio of 11. There is also a high degree of concordance in monozygotic twins. Daughters of index women have the highest relative risk for the development of primary biliary cholangitis.
Several human leukocyte antigen (HLA) allele associations have been reported with primary biliary cirrhosis, which includes DRB1, DR3, DPB1, DQA1, and DQB1. HLA-DRB1*08 is common in European and Asian descent, whereas HLA-DRB1*11 has been found to be protective.
Market Dynamics: Drivers and Restraints
Increasing R&D for the development of new drug therapeutics for primary biliary cholangitis
Currently, there is no cure for primary biliary cholangitis, but various treatments can slow its progression. Pharmaceutical companies are investing heavily in R&D to develop more effective treatments for primary biliary cholangitis. Hence there are a lot of new things, like new medications in development. Seladelpar is in a phase 3 trial that is close to enrollment. Elafibranor is in a phase 3 trial that’s close to enrollment. These are PPAR and PPAR-⍺ dual agonists. Saroglitazar, which is a PPAR-⍺-γ dual agonist, is also in clinical trials. There’s a fixed-dose combination study that’s ongoing with obeticholic acid and bezafibrate.
For instance, in September 2023, CymaBay Therapeutics Inc. (CBAY) stated positive results from its Phase 3 pivotal RESPONSE study of seladelpar in primary biliary cholangitis. The study evaluated the safety and efficacy of seladelpar, a potent, selective, orally active delpar or PPARd agonist, in development for the treatment of adult patients with primary biliary cholangitis.
Furthermore, primary biliary cholangitis is a chronic condition that requires long-term management hence this market is driven by other factors like a rise in the prevalence of primary biliary cholangitis, Advancements in primary biliary cholangitis treatment, growing awareness about primary biliary cholangitis and others.
Market Dynamics: Restraint
Complications are involved with primary biliary cholangitis which indeed hamper the market growth along with other restraint factors If primary biliary cholangitis is not treated or advanced, it can lead to osteoporosis, portal hypertension, ascites, vitamin deficiencies, and a slightly increased risk of liver cancer. Osteoporosis is a weakening of bones, portal hypertension increases blood pressure in abdominal blood vessels, ascites buildup causes fluid accumulation, and vitamin deficiencies increase the risk of liver cancer.
Also, lack of awareness regarding primary biliary cholangitis, early diagnosis of primary biliary cholangitis, and limited treatment options are expected to hinder the growth of the primary biliary cholangitis therapeutics market.
For more details on this report – Request for Sample
Segment Analysis
The global primary biliary cholangitis is segmented based on stage type, drug type, route of administration, distribution channel and region.
The Ursodeoxycholic acid (UDCA) from the drug type segment accounted for approximately 41.2% of the market share
The Ursodeoxycholic acid (UDCA) from the drug type segment accounted for 41.2% and it is expected to dominate during the forecast period. Ursodeoxycholic acid (UDCA) is a secondary bile acid, which means that it is a bacterial metabolite of primary bile acids produced in the liver. It is a C7 epimer of chenodeoxycholic acid, one of the two primary human bile acids. Ursodeoxycholic acid (UCDA) is the only approved first-line treatment for primary biliary cholangitis, slowing disease progression and reducing Liver Transplantation need. Long-term outcomes assessment is challenging due to slow clinical progression.
For instance, in June 2023, Ipsen and GENFIT stated positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, Primary Biliary Cholangitis, who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to well-established healthcare infrastructure, presence of key market players and recent product launches. Moreover, the growing number of patients with primary biliary cirrhosis and the growing demand for therapeutics are anticipated to fuel the market growth over the forecast period.
For instance, in July 2023, Gannex Pharma Co., Ltd, a wholly-owned company of Ascletis Pharma Inc. stated that the completion of enrollment of 98 patients with primary biliary cholangitis in the Phase II clinical trial of ASC42, a novel Farnesoid X receptor (FXR) agonist.
Moreover, in June 2023, Intercept Pharmaceuticals, Inc stated a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis (NASH)-related investment.
COVID-19 Impact Analysis
The COVID-19 pandemic affected the primary biliary cholangitis therapeutics industry negatively, such as various healthcare industries being affected due to the postponement of non-emergency services. The pandemic has disrupted research activities, including clinical trials, restrictions on patient recruitment and new product development.
However, with the relaxation in lockdowns and the decline in COVID-19 cases, companies have re-started their processes to meet the demand for primary biliary cholangitis therapeutics. In addition, the rise in product approvals, and the increase in research and development of advanced medicine of primary biliary cholangitis therapeutics drive the growth of the primary biliary cholangitis therapeutics market.
Competitive Landscape
The major global players in the primary biliary cholangitis market include Intercept Pharmaceuticals, Inc., Ice Pharma, Sun Pharma, Wellona Pharma, Zoic Life Sciences, Steris Healthcare, Cadila Pharma, Cipla, Brunet, AstraEureka Pharmaceuticals and among others.
Key Developments
 In June 2022, Intercept Pharmaceuticals Inc., declared outcomes from two investigations planned to assess clinical results in patients with primary biliary cholangitis on Ocaliva COBALT, a Phase 3b/4 confirmatory clinical results investigation and HEROES-US, one of two HEROES real-world investigations.
 In May 2022, Intercept Pharmaceuticals, Inc. declared that the earliest patient has been dosed in a Phase 2 investigation assessing a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis who have not accomplished a sufficient biochemical response to ursodeoxycholic acid.
 In May 2022, Intercept Pharmaceuticals, Inc. declared that it has entered into an agreement to market to Advanz Pharma, a pharmaceutical firm with a strategic focus on speciality and hospital pharmaceuticals in Europe, some foreign subsidiaries and rights concerning Intercept's international operations, inclusive of a license to commercialize Ocaliva (obeticholic acid) external of the U.S.
Why Purchase the Report?
• To visualize the global primary biliary cholangitis treatment market segmentation-based stage type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of primary biliary cholangitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global primary biliary cholangitis treatment market report would provide approximately 69 tables, 70 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Stage Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing R&D for the development of new drug therapeutics for primary biliary cholangitis
4.1.1.2. Rise in the prevalence of primary biliary cholangitis
4.1.2. Restraints
4.1.2.1. Complications associated with primary biliary cholangitis
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Stage Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage Type
7.1.2. Market Attractiveness Index, By Stage Type
7.2. Stage 1*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Stage 2
7.4. Stage 3
7.5. Stage 4
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Ursodeoxycholic acid (UDCA)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Obeticholic acid (Ocaliva)
8.4. Fibrates (Tricor)
8.5. Budesonide
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Nasal
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers (ASCs)
10.4. Retail Pharmacies
10.5. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Intercept Pharmaceuticals, Inc
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Ice Pharma
13.3. Sun Pharma
13.4. Wellona Pharma
13.5. Zoic Life Sciences
13.6. Steris Healthcare
13.7. Cadila Pharma
13.8. Cipla
13.9. Brunet
13.10. AstraEureka Pharmaceuticals
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Intercept Pharmaceuticals, Inc, 4. Key Developments, Ice Pharma, Sun Pharma, Wellona Pharma, Zoic Life Sciences, Steris Healthcare, Cadila Pharma, Cipla, Brunet, AstraEureka Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Primary Biliary Cholangitis Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 6 Global Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2022-2033 (US$ Billion)

Table 8 Global Primary Biliary Cholangitis Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Primary Biliary Cholangitis Treatment Market Value, By Region, 2022-2033 (US$ Billion)

Table 10 North America Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 11 North America Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2022-2033 (US$ Billion)

Table 12 North America Primary Biliary Cholangitis Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 13 South America Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 14 South America Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2022-2033 (US$ Billion)

Table 15 South America Primary Biliary Cholangitis Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 16 Europe Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 17 Europe Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2022-2033 (US$ Billion)

Table 18 Europe Primary Biliary Cholangitis Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 19 Asia-Pacific Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 20 Asia-Pacific Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Primary Biliary Cholangitis Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 22 Middle East and Africa Primary Biliary Cholangitis Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)

Table 23 Middle East and Africa Primary Biliary Cholangitis Treatment Market Value, By Age Group, 2022-2033 (US$ Billion)

Table 24 Middle East and Africa Primary Biliary Cholangitis Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 Intercept Pharmaceuticals, Inc.: Overview

Table 26 Intercept Pharmaceuticals, Inc.: Product Portfolio

Table 27 Intercept Pharmaceuticals, Inc.: Key Developments

Table 28 Gilead Sciences, Inc.: Overview

Table 29 Gilead Sciences, Inc.: Product Portfolio

Table 30 Gilead Sciences, Inc.: Key Developments

Table 31 Ipsen Biopharmaceuticals, Inc.: Overview

Table 32 Ipsen Biopharmaceuticals, Inc.: Product Portfolio

Table 33 Ipsen Biopharmaceuticals, Inc.: Key Developments

Table 34 Teva Pharmaceuticals USA, Inc.: Overview

Table 35 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 36 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 37 Glenmark Pharmaceuticals Inc.: Overview

Table 38 Glenmark Pharmaceuticals Inc.: Product Portfolio

Table 39 Glenmark Pharmaceuticals Inc.: Key Developments

Table 40 AbbVie Inc.: Overview

Table 41 AbbVie Inc.: Product Portfolio

Table 42 AbbVie Inc.: Key Developments

Table 43 Aden Healthcare: Overview

Table 44 Aden Healthcare: Product Portfolio

Table 45 Aden Healthcare: Key Developments

Table 46 Zydus Therapeutics Inc.: Overview

Table 47 Zydus Therapeutics Inc.: Product Portfolio

Table 48 Zydus Therapeutics Inc.: Key Developments

Table 49 COUR Pharmaceuticals. Overview

Table 50 COUR Pharmaceuticals. Product Portfolio

Table 51 COUR Pharmaceuticals. Key Developments

Table 52 Kowa Company, Ltd.: Overview

Table 53 Kowa Company, Ltd.: Product Portfolio

Table 54 Kowa Company, Ltd.: Key Developments

Table 55 Mirum Pharma: Overview

Table 56 Mirum Pharma: Product Portfolio

Table 57 Mirum Pharma: Key Developments

Table 58 Parvus Therapeutics Inc: Overview

Table 59 Parvus Therapeutics Inc: Product Portfolio

Table 60 Parvus Therapeutics Inc: Key Developments

Table 61 GSK plc.: Overview

Table 62 GSK plc.: Product Portfolio

Table 63 GSK plc.: Key Developments

Table 64 Strides Pharma Science Limited: Overview

Table 65 Strides Pharma Science Limited: Product Portfolio

Table 66 Strides Pharma Science Limited: Key Developments

Table 67 Calliditas Therapeutics AB.: Overview

Table 68 Calliditas Therapeutics AB.: Product Portfolio

Table 69 Calliditas Therapeutics AB.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Primary Biliary Cholangitis Treatment Market Share, By Drug Type, 2024 & 2033 (%)

Figure 3 Global Primary Biliary Cholangitis Treatment Market Share, By Age Group, 2024 & 2033 (%)

Figure 4 Global Primary Biliary Cholangitis Treatment Market Share, By Region, 2024 & 2033 (%)

Figure 5 Global Primary Biliary Cholangitis Treatment Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)

Figure 6 Obeticholic Acid Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 7 Seladelpar Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 8 Elafibranor Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 9 Ursodeoxycholic Acid (UDCA) Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 10 Others Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 11 Global Primary Biliary Cholangitis Treatment Market Y-o-Y Growth, By Age Group, 2023-2033 (%)

Figure 12 Adults Age Group in Global Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 13 Geriatrics Age Group in Global Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 14 Global Primary Biliary Cholangitis Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 15 North America Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 16 North America Primary Biliary Cholangitis Treatment Market Share, By Drug Type, 2024 & 2033 (%)

Figure 17 North America Primary Biliary Cholangitis Treatment Market Share, By Age Group, 2024 & 2033 (%)

Figure 18 North America Primary Biliary Cholangitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 19 South America Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 20 South America Primary Biliary Cholangitis Treatment Market Share, By Drug Type, 2024 & 2033 (%)

Figure 21 South America Primary Biliary Cholangitis Treatment Market Share, By Age Group, 2024 & 2033 (%)

Figure 22 South America Primary Biliary Cholangitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 23 Europe Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 24 Europe Primary Biliary Cholangitis Treatment Market Share, By Drug Type, 2024 & 2033 (%)

Figure 25 Europe Primary Biliary Cholangitis Treatment Market Share, By Age Group, 2024 & 2033 (%)

Figure 26 Europe Primary Biliary Cholangitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 27 Asia-Pacific Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 28 Asia-Pacific Primary Biliary Cholangitis Treatment Market Share, By Drug Type, 2024 & 2033 (%)

Figure 29 Asia-Pacific Primary Biliary Cholangitis Treatment Market Share, By Age Group, 2024 & 2033 (%)

Figure 30 Asia-Pacific Primary Biliary Cholangitis Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 31 Middle East and Africa Primary Biliary Cholangitis Treatment Market Value, 2022-2033 (US$ Billion)

Figure 32 Middle East and Africa Primary Biliary Cholangitis Treatment Market Share, By Drug Type, 2024 & 2033 (%)

Figure 33 Middle East and Africa Primary Biliary Cholangitis Treatment Market Share, By Age Group, 2024 & 2033 (%)

Figure 34 Intercept Pharmaceuticals, Inc.: Financials

Figure 35 Gilead Sciences, Inc.: Financials

Figure 36 Ipsen Biopharmaceuticals, Inc.: Financials

Figure 37 Teva Pharmaceuticals USA, Inc.: Financials

Figure 38 Glenmark Pharmaceuticals Inc.: Financials

Figure 39 AbbVie Inc.: Financials

Figure 40 Aden Healthcare: Financials

Figure 41 Zydus Therapeutics Inc.: Financials

Figure 42 COUR Pharmaceuticals. Financials

Figure 43 Kowa Company, Ltd.: Financials

Figure 44 Mirum Pharma: Financials

Figure 45 Parvus Therapeutics Inc: Financials

Figure 46 GSK plc.: Financials

Figure 47 Strides Pharma Science Limited: Financials

Figure 48 Calliditas Therapeutics AB.: Financials

세계 원발성 담즙성 담관염 치료 시장 – 2023-2030

Global Primary Biliary Cholangitis Treatment Market -2023-2030